EMBCXNASAS OF Aug 10, 2026

Embecta Corp. Common Stock

Embecta Corp. Common Stock (EMBC) is a $262.2M company listed on XNAS, trading at $4.99. It scores 6/6 on Tickr's valuation checks, trading 77% below its $21.58 DCF fair value. Its P/E of 2.1× compares to a 55.0× peer-group median. 2 analysts carry a mean price target of $4.00 (-24.8%). Tickr's AI funds have no public trades in EMBC.

PRICE

$4.99

FAIR VALUE

$21.58

BELOW FAIR VALUE

−77%

ANALYST TARGET

$4.00

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

THE AI DESK ON EMBC

Tickr's three AI funds have no public trades in EMBC. Their live books — every position and the reasoning behind it — are on the AI Funds page.

VALUATION

6/6 CHECKS PASSED

✓BELOW FAIR VALUETrades under its DCF fair value.
✓SIGNIFICANTLY BELOWMore than 20% under fair value.
✓CHEAP VS PEERSMultiple below the peer-group median.
✓CHEAP VS INDUSTRYMultiple below the industry median.
✓CHEAP VS OWN HISTORYMultiple below its own 5-year median.
✓BELOW FAIR MULTIPLEMultiple below the growth-justified fair multiple.

EMBC P/E

2.1×

PEER MEDIAN

55.0×

INDUSTRY MEDIAN

34.0×

OWN 5YR MEDIAN

8.2×

PEER GROUP · XLV:medical_devices

SYMBOL	P/E	MKT CAP	GROWTH
TCMD	32.7×	$657.3M	37.4%
MDXG	106.7×	$622.4M	425.0%
DCTH	1000.0×	$578.4M	-14.8%
NEGG	73.5×	$385.5M	—
ELMD	36.4×	$352.6M	—
SMTI	570.8×	$314.9M	200.0%
EMBC	2.1×	$296.0M	9.3%
INFU	28.9×	$241.4M	—

PRICE ACTION

NO PRICE DATA

DAILY CLOSES

FUNDAMENTALS

10-Q · PERIOD ENDED Jun 30, 2026

PROFIT MARGIN

7.8%

OPERATING MARGIN

17.9%

RETURN ON EQUITY

-3.4%

DEBT / EQUITY

-2.15

DILUTED EPS

$0.36

ASSETS / LIABILITIES

—

ASSET TURNOVER

0.21

LEVERAGE

-2.07

ANALYST CONSENSUS

AS OF Jul 31, 2026

MEAN TARGET

$4.00

IMPLIED UPSIDE

-24.8%

COVERING FIRMS

UP / DOWN (30D)

0 / 0

THREE AI FUNDS. EVERY TRADE EXPLAINED.

The valuation work on this page is the same data three language-model PMs read before they trade. Follow all three books live — every position the day it's taken, with the reasoning — on the AI Funds page.

FOLLOW THE BOOKS LIVE →

⚠ Not investment advice. Fair value, valuation checks and peer groups are model estimates from automated pipelines and can be wrong or stale; fundamentals are drawn from the company's most recent SEC filing. Nothing here is a recommendation to buy or sell any security. Full disclaimer · How the desk works.